ChromaDex (CDXC)
(Delayed Data from NSDQ)
$3.78 USD
0.00 (0.00%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $3.77 -0.01 (-0.26%) 5:38 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Brokerage Reports
ChromaDex Corporation [CDXC]
Reports for Purchase
Showing records 21 - 40 ( 123 total )
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Solid 3Q Results, Cautious 4Q Guidance Points to Strong Growth in 2024
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Top-Line Miss, Bottom-Line Beat; 3Q23 Financials; Reiterating Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Revenue In Line, Bottom-Line Beat; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Solid 2Q: Positive Cash Flow Driven By Modest "Beats" On Most Metrics
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q1 Stronger Than Expected; With Good Revenue Momentum and Cost Discipline
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Record Quarterly Revenue; Lukewarm Outlook; Adjusting PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q4 Sales, Op. Inc. in Line; Posts First Positive Adj. Quarterly EBITDA
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
35th Annual ROTH MKM Conference - Consumer Track - March 12-14
Provider: Roth Capital Partners, Inc.
Analyst: KORANDA M
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Nicotinamide Riboside Cocktail Aids Alzheimer''s Cognition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Cash Flow Breakeven Status Possibly Imminent; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
3Q Results and 4Q Guidance Show Company on the Cusp of Positive EBITDA
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Separating Manufacturing from Design the Next Step in INTC?s Turn-a-Round
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Strengthens Balance Sheet With Additional Cash, Bolsters Entry Into China
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Revenue Miss; Revised Growth Trajectory; Lowering PT to $5.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R